Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30163000 | 1.00 | TTR (0.55) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL24730423 | 0.82 | TTR (0.50) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL130450 | 0.78 | TTR (0.61) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL7351246 | 0.78 | CA2 (0.52) | TTRENPP2CA1CA2TSHR | |
| Phenylboronic Acid SCHEMBL25209043 | 0.75 | ENPP2 (0.48) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL24165 | 0.74 | TTR (0.57) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL16654491 | 0.74 | CA2 (0.48) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL1128990 | 0.73 | CA1 (0.46) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL3190381 | 0.73 | TTR (0.55) | TTRENPP2CA1CA2TSHR | |
| SCHEMBL10137322 | 0.73 | TTR (0.55) | TTRENPP2CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-108409773-B | Triazine group-containing compound, application thereof and organic electroluminescent device | 北京绿人科技有限责任公司 | 2021-02-09 | — | — | CN | disclosed |
| EP-2744342-B1 | THERAPEUTIC METHODS | GLAXOSMITHKLINE LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10238678-B2 | Therapeutic methods | GLAXOSMITHKLINE LLC (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3199531-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| US-9682999-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20150320777-A1 | Therapeutic Methods | GLAXOSMITHKLINE LLC | 2015-11-12 | — | — | US | disclosed |
| US-9119868-B2 | Therapeutic methods | GLAXOSMITHKLINE LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-8927593-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20140212384-A1 | Therapeutic Methods | GLAXOSMITHKLINE LLC | 2014-07-31 | — | — | US | disclosed |
| EP-2744332-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| EP-2744342-A1 | THERAPEUTIC METHODS | GlaxoSmithKline LLC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| WO-2013028371-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | GLAXO GROUP LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013025992-A1 | THERAPEUTIC METHODS | GLAXOSMITHKLINE LLC (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | TTR 1509/4885ENPP2 4551/4885CA1 4755/4885 |
| US-20150320777-A1 | Therapeutic Methods | HAVCR2, SLC10A1, OAT | TTR 222/4885ENPP2 1266/4885CA1 1317/4885 |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | TTR 1509/4885ENPP2 4551/4885CA1 4755/4885 |
| US-10238678-B2 | Therapeutic methods | HAVCR2, SLC10A1, OAT | TTR 222/4885ENPP2 1266/4885CA1 1317/4885 |
| US-20140212384-A1 | Therapeutic Methods | HAVCR2, SLC10A1, OAT | TTR 222/4885ENPP2 1266/4885CA1 1317/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | TTR 3283/4885ENPP2 427/4885CA1 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.